{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:53:50Z","timestamp":1762376030729,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.bcmd.2015.11.003","type":"journal-article","created":{"date-parts":[[2015,11,27]],"date-time":"2015-11-27T02:47:23Z","timestamp":1448592443000},"page":"35-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging"],"prefix":"10.1016","volume":"57","author":[{"given":"K.","family":"Laudemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Moos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mengel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lollert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Brixius-Huth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"D\u00fcber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Staatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcmd.2015.11.003_bb0005","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"93","author":"Hollak","year":"1994","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.bcmd.2015.11.003_bb0010","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2214\/ajr.179.4.1790961","article-title":"Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter","volume":"179","author":"Maas","year":"2002","journal-title":"AJR Am. J. Roentgenol."},{"issue":"6","key":"10.1016\/j.bcmd.2015.11.003_bb0015","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1182\/blood-2011-04-308890","article-title":"How I treat Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcmd.2015.11.003_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0010021","article-title":"Enzyme replacement in Gaucher disease","volume":"1","author":"Beutler","year":"2004","journal-title":"PLoS Med."},{"issue":"11","key":"10.1016\/j.bcmd.2015.11.003_bb0025","first-page":"979","article-title":"MRT der knochenmarkver\u00e4ndungen bei 63 patienten mit morbus gaucher Typ I","volume":"182","author":"Poll","year":"2010","journal-title":"R\u00f6Fo: Fortschritte auf dem Gebiete der R\u00f6ntgenstrahlen und der Nuklearmedizin"},{"issue":"5","key":"10.1016\/j.bcmd.2015.11.003_bb0030","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/00004728-200209000-00031","article-title":"Vertebra disc ratio as a parameter for bone marrow involvement and its application in Gaucher disease","volume":"26","author":"Vlieger","year":"2002","journal-title":"J. Comput. Assist. Tomogr."},{"issue":"1","key":"10.1016\/j.bcmd.2015.11.003_bb0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/GIM.0b013e3181c39194","article-title":"A validated disease severity scoring system for adults with type 1 Gaucher disease","volume":"12","author":"Weinreb","year":"2009","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.bcmd.2015.11.003_bb0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/glycob\/cwp138","article-title":"Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages","volume":"20","author":"Brumshtein","year":"2010","journal-title":"Glycobiology"},{"issue":"1","key":"10.1016\/j.bcmd.2015.11.003_bb0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bcmd.2011.09.009","article-title":"Booster-effect with Velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early access program results from Jerusalem","volume":"48","author":"Elstein","year":"2012","journal-title":"Blood Cells Mol. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.bcmd.2015.11.003_bb0050","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1259\/bjr.75.suppl_1.750025","article-title":"Response of Gaucher bone disease to enzyme replacement therapy","volume":"75","author":"Poll","year":"2002","journal-title":"Br. J. Radiol."},{"issue":"9","key":"10.1016\/j.bcmd.2015.11.003_bb0055","first-page":"565","article-title":"Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy","volume":"86","author":"Zevin","year":"1993","journal-title":"Q. J. Med."},{"issue":"2","key":"10.1016\/j.bcmd.2015.11.003_bb0060","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2292020296","article-title":"Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging\u2014initial experience","volume":"229","author":"Maas","year":"2003","journal-title":"Radiology"},{"issue":"Suppl. 1","key":"10.1016\/j.bcmd.2015.11.003_bb0065","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1259\/bjr.75.suppl_1.750013","article-title":"Imaging and quantifying skeletal involvement in Gaucher disease","volume":"75","author":"Maas","year":"2002","journal-title":"Br. J. Radiol."},{"issue":"3","key":"10.1016\/j.bcmd.2015.11.003_bb0070","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ajh.23383","article-title":"Safety and efficacy of Velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase","volume":"88","author":"Zimran","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.bcmd.2015.11.003_bb0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.23382","article-title":"Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease","volume":"88","author":"Ben Turkia","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.bcmd.2015.11.003_bb0080","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1148\/radiology.182.2.1732964","article-title":"Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease","volume":"182","author":"Johnson","year":"1992","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.bcmd.2015.11.003_bb0085","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1185\/030079906X104623","article-title":"Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients*","volume":"22","author":"Vom Dahl","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"issue":"12","key":"10.1016\/j.bcmd.2015.11.003_bb0090","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3324\/haematol.2011.059071","article-title":"Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes","volume":"97","author":"van Dussen","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bcmd.2015.11.003_bb0095","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s10545-006-0121-6","article-title":"Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients","volume":"29","author":"El-Beshlawy","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"9","key":"10.1016\/j.bcmd.2015.11.003_bb0100","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s002560100375","article-title":"Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results","volume":"30","author":"Poll","year":"2001","journal-title":"Skelet. Radiol."},{"issue":"1","key":"10.1016\/j.bcmd.2015.11.003_bb0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcmd.2010.10.005","article-title":"Whole body MRI in type I Gaucher patients: evaluation of skeletal involvement","volume":"46","author":"Poll","year":"2011","journal-title":"Blood Cell Mol. Dis."},{"issue":"9","key":"10.1016\/j.bcmd.2015.11.003_bb0110","first-page":"653","article-title":"A retrospective study on enzyme replacement therapy in patients with Gaucher disease","volume":"44","author":"Duan","year":"2006","journal-title":"Zhonghua er ke za zhi Chin. J. Pediatr."},{"issue":"6","key":"10.1016\/j.bcmd.2015.11.003_bb0115","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2214\/AJR.06.1410","article-title":"Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score","volume":"188","author":"Robertson","year":"2007","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.bcmd.2015.11.003_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2014.02.006","article-title":". Impact of Velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-Year follow-up","author":"Elstein","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"issue":"2","key":"10.1016\/j.bcmd.2015.11.003_bb0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.crad.2003.09.010","article-title":"Gaucher disease in children: radiology of non-central nervous system manifestations","volume":"59","author":"McHugh","year":"2004","journal-title":"Clin. Radiol."},{"issue":"2","key":"10.1016\/j.bcmd.2015.11.003_bb0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/bcmd.2002.0511","article-title":"Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients","volume":"28","author":"Poll","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"issue":"3","key":"10.1016\/j.bcmd.2015.11.003_bb0135","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","article-title":"The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease","volume":"71","author":"Charrow","year":"2007","journal-title":"Clin. Genet."},{"issue":"5","key":"10.1016\/j.bcmd.2015.11.003_bb0140","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.berh.2011.10.015","article-title":"Miscellaneous non-inflammatory musculoskeletal conditions. Gaucher disease and bone","volume":"25","author":"Mikosch","year":"2011","journal-title":"Best Pract. Res. Clin. Rheumatol."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979615300115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979615300115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:31:47Z","timestamp":1761049907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979615300115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":28,"alternative-id":["S1079979615300115"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2015.11.003","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2015.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}